You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR genetic aberration

Showing 1 - 25 of 7,540
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Urothelial Carcinoma Trial in Worldwide (Derazantinib dose level 1 (300mg once daily) monotherapy, Derazantinib various dose

Completed
  • Urothelial Carcinoma
  • Derazantinib dose level 1 (300mg once daily) monotherapy
  • +4 more
  • Newnan, Georgia
  • +65 more
Oct 19, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

Completed
Has Results
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 8, 2021

Gastric Adenocarcinoma Trial in Worldwide (Derazantinib, Derazantinib-paclitaxel-ramucirumab, Derazantinib-atezolizumab)

Completed
  • Gastric Adenocarcinoma
  • Orlando, Florida
  • +80 more
Jan 13, 2023

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Intrahepatic Cholangiocarcinoma Trial (Famitinib)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
Jun 16, 2021

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

Recruiting
  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • FGFR Testing
  • Calgary, Alberta, Canada
  • +6 more
Nov 8, 2023

Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter Trial in Spain, United States (PRN1371)

Terminated
  • Solid Tumors
  • Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
  • San Francisco, California
  • +11 more
Dec 23, 2020

Clinical Utility of Oncomine Precision Assay Within Exactis

Recruiting
  • NSCLC
    • Moncton, New Brunswick, Canada
    • +6 more
    Dec 9, 2022

    Bladder Urothelial Cancer Trial in China (ICP-192)

    Recruiting
    • Bladder Urothelial Cancer
    • Hefei, Anhui, China
    • +9 more
    Oct 20, 2021

    Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Tumors (MLN)

    Active, not recruiting
    • Advanced or Metastatic Solid Tumor
    • +2 more
    • Gilbert, Arizona
    • +60 more
    Oct 20, 2022

    Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

    Recruiting
    • Salivary Gland Cancer
    • +3 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Feb 18, 2022

    Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

    Active, not recruiting
    • Squamous-cell Non-small Cell Lung Cancer
    • Baden, Switzerland
    • +10 more
    Jan 20, 2022

    Advanced and Metastatic Urothelial Cancer Trial in France, Spain, United States (futibatinib and pembrolizumab)

    Recruiting
    • Advanced and Metastatic Urothelial Cancer
    • futibatinib and pembrolizumab
    • San Francisco, California
    • +17 more
    Oct 25, 2022

    Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

    Recruiting
    • Bladder Cancer
    • +12 more
    • Raleigh, North Carolina
      xCures Virtual Site
    Sep 20, 2021

    A Taiwanese Oncogenetic Panel and Integrated Clinical Data

    Recruiting
    • Thyroid Cancer
    • A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
    • Kaohsiung, Taiwan
    • +7 more
    Sep 12, 2022

    Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +44 more
    • Biopsy
    • +23 more
    • Birmingham, Alabama
    • +166 more
    Feb 2, 2023

    Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

    Not yet recruiting
    • Cholangiocarcinoma
    • Tinengotinib 8 mg
    • +2 more
    • Santa Monica, California
    • +13 more
    Jul 7, 2023

    Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +49 more
    • Birmingham, Alabama
    • +1429 more
    Aug 17, 2022

    Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma Trial in Australia, United States (Drug ICP-192)

    Recruiting
    • Advanced Solid Tumors
    • +2 more
    • Drug ICP-192
    • Tucson, Arizona
    • +8 more
    Jan 28, 2022

    Central and Peripheral Wavefront Aberration Profile in Pediatric

    Not yet recruiting
    • Myopia
    • Intervention
    • Houston, Texas
      University of Houston College of Optometry - J. Armistead Bldg R
    Oct 9, 2023

    Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)

    Recruiting
    • Advanced or Recurrent Solid Tumors
    • FGFR Gene Alterations
    • Aoba-ku, Sendai, Miyagi, Japan
    • +4 more
    May 9, 2022